Compugen Ltd. (NASDAQ:CGEN) shares dropped 3.4% during trading on Tuesday . The company traded as low as $6.72 and last traded at $6.84, with a volume of 139,646 shares changing hands. The stock had previously closed at $7.08.

CGEN has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded shares of Compugen from a “sell” rating to a “hold” rating in a research report on Tuesday, August 2nd. FBR & Co restated a “buy” rating on shares of Compugen in a research report on Wednesday, June 22nd. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Compugen currently has a consensus rating of “Buy” and an average target price of $10.25.

The stock has a 50-day moving average of $6.66 and a 200 day moving average of $6.20. The company’s market capitalization is $344.65 million.

Compugen (NASDAQ:CGEN) last issued its quarterly earnings data on Tuesday, August 2nd. The company reported ($0.13) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.17) by $0.04. Equities research analysts predict that Compugen Ltd. will post ($0.56) EPS for the current fiscal year.

Compugen Ltd. (Compugen) is a therapeutic discovery company. The Company focuses on the discovery and development of monoclonal antibodies (mAbs) and therapeutic proteins in the fields of oncology and immunology. Its pipeline program consists of drug targets and therapeutic product candidates at various stages ranging from target validation to pre-clinical studies in the fields of oncology and immunology, with a primary focus on immuno-oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.